How Federal Agency Voice Solutions Went from On-Premise to the Cloud

Not many people have the opportunity to do business with government agencies, and even fewer have the privilege to do so at the federal level.

Bill Grabner, however, has done this for over 20 years.

Before coming to Ribbon Communications about a year ago, Grabner, spent much of his career conducting sales with the federal government and the public sector overall at companies like Cisco and Genesis. Today, as Ribbon’s vice president of federal markets, he leverages his 20-plus years of experience to explain the intricacies of federal agency voice solutions.

Compared to commercial organizations, the public sector — and federal agencies in particular — have a different set of needs and restrictions when it comes to their voice applications, which makes a migration to the cloud a challenge.

“The federal government has a different use case than their commercial counterparts, and I think that vendors haven’t done a good job of solving that problem for them,” mused Grabner.

“And it’s a bit of a chicken and the egg — without products available, federal agencies haven’t gone to market looking for those products quite as much. And without the federal government going to market, OEM vendors and contractors haven’t put as much effort and focus into that.”

Another issue lies in the need for federal communication lines to be always available, especially during emergencies.

“Governments still need to be operational, and for agencies more concerned with national security, like the Department of Defense commands… They have a mandate. They have to operate in the event of some sort of a cloud outage,” he revealed.

“The federal government, and a lot of public sector agencies in general, need to have a hybrid environment and OEM vendors have not done a really good job of creating a hybrid environment for them.”

For the latest insights from Ribbon Communications and thought leaders in the telecommunications industry, make sure to visit our website for our blog posts, case studies, webinars, and more.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More